JACOBSON PHARMA2633.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, JACOBSON PHARMA (2633.HK) trades at a P/E of 6.36x, P/B of 0.83x, P/S of 1.22x, and a dividend yield of 16.40%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/B sits at the 40th percentile over the trailing 10Y window (vs. 41st percentile over 3Y); P/S sits at the 38th percentile over the trailing 10Y window (vs. 40th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 16th percentile within its industry and the 26th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 16.40%, ranking at the 100th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 26.0 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. JACOBSON PHARMA operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2633 · SEHK: 2633 · 2633
Want the full picture on whether JACOBSON PHARMA (2633.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 6.36 | ||||||
| P/B (MRQ) | 0.83 | ||||||
| P/S (TTM) | 1.22 | ||||||
| Dividend Yield | 16.40% | ||||||
| Buyback + Div Yield | 16.40% |